Lonza: 'We are platform and modality agnostic'
The move demonstrates how the company is “staying at the forefront of innovation,” Jean-Christophe Hyvert, president of biologics at Lonza, tells Bio-Pharma Reporter at Bio International 2023.
“We are leaders in commercial product for ADCs and acquiring Synaffix is an exciting development. At Lonza, we are able to stay ahead in the industry by providing end-to-end solutions, whether that’s helping customers manage life cycle or development. We are able to take a customer early on, when they have a molecule, through development and manufacturing, all the way to clinical, commercial, and managing the end to end offering.”
As Lonza is comprised of various different platforms, it is able to provide "integrated solutions" for its customers, allowing them to stay within the company, rather than doing various changes and transfers, Hyvert adds.
Another differentiating factor is that Lonza is active in “pretty much all modalities” and customers can benefit from this breadth and variety.
“We are platform agnostic and modality agnostic. We can do small scale, large scale, stainless steel is possible. This means we can do what is right for the customer and the molecule,” Hyvert adds.
“While many of our competitors tend to have one platform, we don’t have a vested interest in one modality or path. We want to find the right solution for a specific given product.”
Having comprehensive discussions with customers remains a top priority for Hyvert – to identify what they wish to prioritize and develop.
“Do they want to prioritize decision making along the way? Do they want to prioritize speed? Do they know what level of risk or parallel processing they willing to do to achieve a given outcome? This is what we are pushing right now – to have a close connection with our customers so we understand their needs and can adapt our processes.”
